CN Patent

CN118973559A — 米达美替尼的非线性给药

Assigned to Springworths Treatment Co ltd · Expires 2024-11-15 · 2y expired

What this patent protects

本公开涉及用于通过诸如通过某种给药方案向有需要的患者施用米达美替尼或其药学上可接受的盐来治疗某些类型的肿瘤或癌症诸如丛状神经纤维瘤(PN)、与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法。

USPTO Abstract

本公开涉及用于通过诸如通过某种给药方案向有需要的患者施用米达美替尼或其药学上可接受的盐来治疗某些类型的肿瘤或癌症诸如丛状神经纤维瘤(PN)、与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN118973559A
Jurisdiction
CN
Classification
—
Expires
2024-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Springworths Treatment Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.